Wedoany.com Report-Dec.22, Novartis has entered into an agreement with the United States government aimed at lowering prices for certain innovative medicines while maintaining support for ongoing investments in manufacturing, research, and development within the country.

Novartis is advancing plans for new radioligand therapy manufacturing facilities in Texas and Florida.

As part of the voluntary commitments, Novartis will introduce future medicines at prices aligned with those in other high-income nations. The company will also create direct-to-patient distribution platforms for Tabrecta (capmatinib), Mayzent (siponimod), and Rydapt (midostaurin), made available through the TrumpRx program.

Furthermore, Novartis intends to participate in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model to enhance medicine access for patients covered by Medicaid.

The agreement includes efforts to promote a more balanced global contribution to pharmaceutical innovation funding.

Novartis CEO Vas Narasimhan said: "This agreement continues our long-term partnership with the US government to advance the development and manufacturing of breakthrough treatments for patients in the United States.

"We are committed to working with governments worldwide to ensure innovation is appropriately valued and that our medicines reach the patients who need them most."

Earlier in the year, Novartis outlined plans to allocate $23 billion over five years toward expanding its research and production capabilities in the United States.

Subsequent announcements detailed a $1.1 billion biomedical research center in San Diego, the start of construction on a major manufacturing complex comprising three sites in the Raleigh/Durham region of North Carolina, and the inauguration of a radioligand therapy production facility in Carlsbad, California.

The company is also progressing with designs for additional radioligand therapy manufacturing plants in Texas and Florida.

These substantial investments are expected to qualify Novartis for three years of tariff relief under the terms of the agreement.

This collaboration reflects ongoing cooperation between the pharmaceutical sector and government authorities to improve medicine affordability and sustain advancement in healthcare solutions.